Brasofensine (NS-2214, BMS-204756) is a phenyltropane dopamine reuptake inhibitor that had been under development by Bristol-Myers Squibb and defunct company NeuroSearch for the treatment of Parkinson's and Alzheimer's diseases. == History == In 1996, brasofensine entered phase I trials in the United States and phase II trials in Denmark.
Brasofensine (NS-2214, BMS-204756) is a phenyltropane dopamine reuptake inhibitor that had been under development by Bristol-Myers Squibb and defunct company NeuroSearch for the treatment of Parkinson's and Alzheimer's diseases. == History == In 1996, brasofensine entered phase I trials in the United States and phase II trials in Denmark.
Source: Wikipedia "Brasofensine" · CC BY-SA 4.0
Share this article: X · Bluesky